GlassScriptPhysician profile
Julius Kpaduwa
NPI 1578630125
$2,707.25
in general payments reported to CMS, 2019-2025
22 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $426 · 2021: $818 · 2022: $244 · 2023: $259 · 2024: $331 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $778.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $900.96 | 2019-2023 | |
| Coopersurgical, INC. | $463.29 | 2019-2022 | |
| Shield Therapeutics INC | $216.48 | 2023-2025 | Accrufer |
| Merck Sharp & Dohme LLC | $161.56 | 2019-2025 | Vaxneuvance, Enflonsia, Rotateq |
| Allergan, INC. | $158.55 | 2019-2020 | |
| Viiv Healthcare Company | $124.99 | 2024 | |
| Exeltis, USA INC. | $123.58 | 2022-2023 | Slynd |
| Sumitomo Pharma America, INC. | $95.07 | 2023-2025 | Myfembree |
| Sanofi Pasteur INC. | $77.30 | 2021-2025 | |
| Glaxosmithkline, LLC. | $58.00 | 2022-2024 | Bexsero, Rotarix |
| Myovant Sciences INC. | $48.82 | 2022 | |
| Roche Diagnostics Corporation | $40.34 | 2019 | |
| Hologic Sales and Service, LLC | $38.14 | 2021 | |
| Cranial Technologies, INC | $33.92 | 2019-2023 | Doc Band |
| Agile Therapeutics, INC. | $28.33 | 2022-2024 | Twirla |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $23.67 | 2023 | Nexplanon |
| Millicent US INC | $22.12 | 2025 | Femlyv |
| Ethicon US, LLC | $20.45 | 2020 | |
| Dexcom, INC. | $19.73 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $18.20 | 2024 | |
| Cipher Pharmaceuticals US LLC | $17.11 | 2025 | Spinosad, Natroba |
| Mylan Pharmaceuticals INC. | $16.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julius Kpaduwa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.